Mumbai — India has granted Pfizer a patent for its powerful pneumonia vaccine Prevnar 13, in a blow to some health groups that say this will put the treatment out of reach of thousands in poorer nations. The decision by India’s patent office bars other companies from making cheaper copies of the vaccine and allows Pfizer to exclusively sell it in India until 2026. It’s a big victory for the US drug maker in a market that has the world’s largest number of pneumonia cases, a lung disease that kills nearly a million children a year globally. Tuesday’s decision also has international implications, as several poorer nations rely on India’s robust drugs industry to supply cheaper copies of medicines and vaccines. Pfizer’s vaccine protects children and adults from 13 types of pneumococcal bacteria, and a full vaccination course costs about $170 on India’s private market. India started giving out the vaccine for free under its national immunisation programme in March, but the roll-out is re...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.